What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Casper H.J. van Eijck mostly deals with Surgery, Pancreatitis, Internal medicine, Randomized controlled trial and Pancreatic cancer.
His Surgery research includes themes of Relative risk and Clinical trial.
His Pancreatitis research integrates issues from Interquartile range, Laparotomy, Acute pancreatitis, Prospective cohort study and Pancreatic disease.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Pancreaticoduodenectomy and Odds ratio.
His Randomized controlled trial research incorporates themes from Functional recovery, Gastric emptying and Treatment outcome.
The Pancreatic cancer study combines topics in areas such as Gemcitabine, Chemoradiotherapy and Confidence interval.
His most cited work include:
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival (1038 citations)
- Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial (931 citations)
- A step-up approach or open necrosectomy for necrotizing pancreatitis (880 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Surgery, Pancreatic cancer, Gastroenterology and Oncology are his primary areas of study.
His work in the fields of Internal medicine, such as Neuroendocrine tumors, Prospective cohort study and Pancreas, intersects with other areas such as In patient.
His research on Surgery frequently connects to adjacent areas such as Pancreatic fistula.
His Pancreatic cancer study combines topics from a wide range of disciplines, such as Cancer research, Radiology and Adenocarcinoma.
The various areas that he examines in his Gastroenterology study include Incidence and Chemotherapy.
His research integrates issues of Pancreatic disease and Acute pancreatitis in his study of Pancreatitis.
He most often published in these fields:
- Internal medicine (41.79%)
- Surgery (34.33%)
- Pancreatic cancer (28.66%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (41.79%)
- Pancreatic cancer (28.66%)
- Surgery (34.33%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Pancreatic cancer, Surgery, Oncology and Randomized controlled trial.
His Internal medicine study frequently involves adjacent topics like Gastroenterology.
His work in Gastroenterology covers topics such as Incidence which are related to areas like Neuroendocrine tumors.
His studies deal with areas such as Gemcitabine, Cancer research, Cancer registry and Immunotherapy as well as Pancreatic cancer.
His Surgery study incorporates themes from Gastric emptying and Carcinoma.
The concepts of his Randomized controlled trial study are interwoven with issues in Necrotizing pancreatitis, Pancreatitis, Clinical trial and MEDLINE.
Between 2018 and 2021, his most popular works were:
- Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2) : a multicentre, patient-blinded, randomised controlled phase 2/3 trial (150 citations)
- Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial. (141 citations)
- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial (132 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
Casper H.J. van Eijck mainly investigates Internal medicine, Pancreatic cancer, Randomized controlled trial, Surgery and FOLFIRINOX.
His study brings together the fields of Gastroenterology and Internal medicine.
His Pancreatic cancer research is multidisciplinary, incorporating perspectives in Cancer registry, Incidence, Oncology, Confidence interval and Gemcitabine.
His work in Randomized controlled trial tackles topics such as Pancreatitis which are related to areas like Quality of life and Clinical endpoint.
His Surgery research incorporates elements of Clinical trial and Carcinoma.
His FOLFIRINOX study integrates concerns from other disciplines, such as Chemoradiotherapy and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
